Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Tandlægeselskabet Colosseumklinikken Odense ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.5% 0.5%   Bankruptcy risk   6.5% 7.2% 8.3% 8.8% 8.7% 2.4% 18.2% 17.9%   Credit score (0-100)   38 35 29 27 27 62 8 8   Credit rating   BBB BBB BB BB BB BBB B B   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   2,288 4,641 4,718 6,842 7,418 7,394 0.0 0.0   EBITDA   -60.7 363 305 1,232 1,016 1,073 0.0 0.0   EBIT   -304 -59.0 -148 328 345 697 0.0 0.0   Pre-tax profit (PTP)   -367.7 -184.1 -233.4 242.1 161.3 686.5 0.0 0.0   Net earnings   -287.0 -143.6 -241.0 242.1 31.0 603.5 0.0 0.0   Pre-tax profit without non-rec. items   -368 -184 -233 242 161 687 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   2,384 1,981 1,657 1,075 894 627 0.0 0.0   Shareholders equity total   -237 -381 -622 -379 -348 255 205 205   Interest-bearing liabilities   889 910 1,056 301 0.0 0.0 0.0 0.0   Balance sheet total (assets)   3,896 3,260 3,528 2,837 1,965 1,669 205 205   Net Debt   16.5 142 -278 -680 -132 -145 -205 -205     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   2,288 4,641 4,718 6,842 7,418 7,394 0.0 0.0   Gross profit growth   0.0% 102.8% 1.7% 45.0% 8.4% -0.3% -100.0% 0.0%   Employees   5 7 8 9 10 10 0 0   Employee growth %   0.0% 40.0% 14.3% 12.5% 11.1% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   3,896 3,260 3,528 2,837 1,965 1,669 205 205   Balance sheet change%   0.0% -16.3% 8.2% -19.6% -30.7% -15.1% -87.7% 0.0%   Added value   -60.7 363.0 305.4 1,232.1 1,248.8 1,073.4 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   2,140 -825 -778 -1,486 -851 -643 -627 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 -2.0 -3.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -13.3% -1.3% -3.1% 4.8% 4.6% 9.4% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -7.3% -1.3% -3.7% 9.0% 12.5% 35.3% 0.0% 0.0%   ROI %   -10.6% -1.9% -5.9% 18.8% 34.8% 95.4% 0.0% 0.0%   ROE %   -7.4% -4.0% -7.1% 7.6% 1.3% 54.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -5.7% -10.5% -15.1% -11.9% -15.1% 15.4% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -27.2% 39.0% -90.9% -55.2% -13.0% -13.5% 0.0% 0.0%   Gearing %   -375.1% -239.0% -170.0% -79.2% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   14.7% 14.9% 9.0% 13.0% 122.2% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.7 0.6 0.6 0.7 0.7 1.2 0.0 0.0   Current Ratio   0.7 0.6 0.6 0.7 0.8 1.2 0.0 0.0   Cash and cash equivalent   872.4 768.0 1,334.0 980.2 132.2 144.5 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -653.6 -826.5 -1,059.6 -729.9 -308.0 200.5 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -12 52 38 137 125 107 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -12 52 38 137 102 107 0 0   EBIT / employee   -61 -8 -19 36 34 70 0 0   Net earnings / employee   -57 -21 -30 27 3 60 0 0